http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 20:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594021.html si-local-file:///var/storage/secattach/20260602/26594021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594021.html Tue, 02 Jun 2026 20:42:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594021.html si-local-file:///var/storage/secattach/20260602/26594021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594021.html Tue, 02 Jun 2026 20:42:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594019.html si-local-file:///var/storage/secattach/20260602/26594019.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594019.html Tue, 02 Jun 2026 20:41:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594019.html si-local-file:///var/storage/secattach/20260602/26594019.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+30++Filed+by%3A+Meehan+Viola+Mong/26594019.html Tue, 02 Jun 2026 20:41:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+29/26592584.html si-local-file:///var/storage/secattach/20260602/26592584.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+29/26592584.html Tue, 02 Jun 2026 16:46:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+29/26592584.html si-local-file:///var/storage/secattach/20260602/26592584.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+May+29/26592584.html Tue, 02 Jun 2026 16:46:00 -0400 CUE O.31243297 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html <p>Cue Biopharma Inc. (NASDAQ: CUE) announced changes to its board of directors as the biotechnology company continues its transition to late-stage clinical capabilities.</p> <p>Four independent directors resigned from the board effective May 29, 2026: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.</p> <p>Camardo brings over 30 years of industry experience and currently serves as President of Immedica Pharma North America, a subsidiary of Swedish biopharma company Immedica Pharma AB. He previously served as CEO at Athersys, a clinical-stage cell therapy company, and held senior executive roles at Astellas http://www.streetinsider.com/Board+Changes/Cue+Biopharma+adds+two+directors+as+four+resign+from+board/26591514.html Tue, 02 Jun 2026 16:05:32 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Announces+Board+Transition+and+Addition+of+New+Directors+with+Continued+Company+Evolution/26591506.html <p align="center"><em>Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board</em></p> <p align="center"><em>Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board </em></p> <p>BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5YvHVj0Pln2vX3iYpE28gzmbg5YhhZPhZ5j87YlZv1jX3puTVPlHdQBtW0aEGfzKI8uc9EUrKt2QKdTK0Smj0mluhZqhl-XUnOHvjWvbAtPSAl7yijReD82vj_APzi1eu-aCXm8MZlmLK1RxT6e0Weh0nlfQK2053ymNLnhDPmu30Dq2eOjMGOvHeLkalwZEk32W6FWEUbpOp023EilE4cs7ukbT99WyV3YUZBWKfL0xgftoXNQitXWt4VlQRY2jUUVbtxckcP9g87uV1jFMbQ==" rel="nofollow" target="_blank">Cue Biopharma, Inc.</a> (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Announces+Board+Transition+and+Addition+of+New+Directors+with+Continued+Company+Evolution/26591506.html Tue, 02 Jun 2026 16:05:00 -0400 A.06372891 A.09408455 A.26756439 A.32945955 A.40132879 A.42701340 A.50200944 A.50209631 CUE O.00417106 O.00477968 O.02490275 O.05016941 O.09922774 O.31243297 O.37571654 O.38699866 O.45210133